|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005516,
umls-concept:C0013216,
umls-concept:C0017262,
umls-concept:C0027651,
umls-concept:C0030705,
umls-concept:C0032854,
umls-concept:C0033325,
umls-concept:C0058126,
umls-concept:C0185117,
umls-concept:C0205251,
umls-concept:C0332293,
umls-concept:C0441767,
umls-concept:C0441889,
umls-concept:C1511562,
umls-concept:C1527249,
umls-concept:C1561558,
umls-concept:C2698872,
umls-concept:C2911684
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2004-1-27
|
|
pubmed:abstractText |
The aim of this study was to evaluate the prognostic significance of tumor dihydropyrimidine dehydroganase (DPD) in curatively resected colorectal cancer patients who received or did not receive oral 5-FU based-adjuvant chemotherapy. Among 182 patients with stage II-III colorectal cancers, 89 patients (adjuvant chemotherapy group) received oral 5-FU based-adjuvant chemotherapy, and 93 patients (surgery alone group) did not receive 5-FU. DPD expressions in the tumors and in the normal colonic mucosa were measured by enzyme-linked immunosorbent assays. The mean DPD expression of the tumors was significantly lower than that of the normal mucosa (54.4 +/- 40.4 versus 72.3 +/- 23.3 Unit/mg protein, P < 0.01). For survival analyses, we designated the cut-off value of tumor DPD as its median value (46.3). In the adjuvant chemotherapy group, high tumor DPD levels were associated with poor survival (HR, 5.24; P = 0.03). In the surgery alone group, high tumor DPD levels were associated with better survival (HR, 0.32; P = 0.02). In conclusion, tumor DPD level is an efficacious marker in oral 5-FU based-adjuvant chemotherapy for colorectal cancer; however, low tumor DPD predicts reduced survival in patients treated with curative surgery alone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0304-3835
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
10
|
|
pubmed:volume |
204
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
97-104
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14744539-Administration, Oral,
pubmed-meshheading:14744539-Adult,
pubmed-meshheading:14744539-Aged,
pubmed-meshheading:14744539-Aged, 80 and over,
pubmed-meshheading:14744539-Antimetabolites, Antineoplastic,
pubmed-meshheading:14744539-Chemotherapy, Adjuvant,
pubmed-meshheading:14744539-Colorectal Neoplasms,
pubmed-meshheading:14744539-Dihydrouracil Dehydrogenase (NADP),
pubmed-meshheading:14744539-Female,
pubmed-meshheading:14744539-Fluorouracil,
pubmed-meshheading:14744539-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:14744539-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:14744539-Humans,
pubmed-meshheading:14744539-Male,
pubmed-meshheading:14744539-Middle Aged,
pubmed-meshheading:14744539-Neoplasm Staging,
pubmed-meshheading:14744539-Prognosis,
pubmed-meshheading:14744539-Survival Rate,
pubmed-meshheading:14744539-Tumor Markers, Biological
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone.
|
|
pubmed:affiliation |
Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto 1-7-1, Nagasaki, 852-8501, Japan. bannv@bolero.plala.or.jp
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
